Alder BioPharmaceuticals is a Bothell, Washington-based developer and manufacturer of novel antibody therapeutics targeting cancer, pain, cardiovascular and autoimmune and inflammatory diseases. Its pipeline includes ALD403, an investigational monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP) to prevent migraine attacks, and ALD518, an investigational monoclonal antibody to the pro-inflammatory cytokine IL-6. The company intends to use the Series D funding to advance ALD403 into the clinic this quarter and to support ongoing Phase 2 studies of ALD518 in cancer-related indications. Alder is led by president and CEO Randall Schatzman, Ph.D. The company closed a $38M Series D financing to support these clinical development plans. Alder Biopharmaceuticals develops antibody-based drugs targeting inflammation and autoimmune disease, with a lead candidate ALD518 in clinical trials for rheumatoid arthritis and cancer. The company uses a yeast-based manufacturing platform to produce full-length functioning antibodies at industrial scale, which it says is faster and cheaper than mammalian-cell methods. Alder claims yeast production can shorten development timelines from years to months and avoid expensive patent licenses tied to traditional techniques. That platform is intended to allow evaluation of a wider range of antibody candidates. Financially, the company completed a third funding round that raised $40 million. The articles do not disclose revenue or other operating metrics.

Total raised

$78M

Funding rounds

2

Latest round

Series D

Latest activity

Apr 2012